Could a peptide supercharge COVID-19 vaccines for seniors?

NCT ID NCT06821100

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: The Methodist Hospital Research Institute Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether an experimental immune-boosting peptide called thymalfasin (Ta1) can safely enhance the immune response to a COVID-19 mRNA booster shot in adults aged 65 and older. Participants receive different doses of Ta1 before vaccination to see if it improves antibody levels. The main goal is to check safety and tolerability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental immune-boosting peptide called thymalfasin (also known as thymosin alpha 1 or Ta1)
What this could lead to: If it works, this could point toward a way to strengthen vaccine protection in older adults, who often have weaker immune responses.
What could go wrong: This is an early Phase 1 trial focused on safety, so it is too small to prove whether Ta1 actually improves vaccine response. The benefit remains uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 VACCINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 VACCINE IMMUNE RESPONSE TO COVID 19 VACCINATION VACCINE RESPONSE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Houston Methodist Hospital
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.